Day: February 22, 2026

The intensive exploration campaign aims to extend known mineralisation, drill recently defined targets and identify new prospects as part of the strategy to drive value through resource growth Chibougamau Copper-Gold Project, Canada HIGHLIGHTS:Cygnus sets up value drivers for 2026 with exploration and resource growth a high priority At Cedar Bay, Downhole Electromagnetics (‘DHEM’) is in progress to identify follow-up targets from recent intersections1 such as:28.9m at 2.5g/t AuEq (1.0g/t Au, 1.0% Cu & 12.0g/t Ag) (CDR-25-16) 10.6m at 4.1g/t AuEq (3.6g/t Au, 0.3% Cu & 2.8g/t Ag) (CDR-25-11W1)This is the first time DHEM is being used at Cedar Bay in over 20 years Drilling has started at Golden Eye to test extensions below the current resource, which stands at 0.5Mt at 5.6g/t AuEq for 91koz AuEq (Indicated) and 1.2Mt at...

– Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD – – Oral presentation on Phase 3 trial design for z-basivarsen in DM1 – – Five total presentations across three neuromuscular diseases demonstrate strength of Dyne’s pipeline based on clinically-validated FORCE™ platform – WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that five presentations, including three oral presentations, highlighting the company’s Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease programs will be presented at the...

CALGARY, Alberta, Feb. 22, 2026 (GLOBE NEWSWIRE) — (“Canacol” or the “Company”) announces a leadership change and the appointment of an independent director to the board of directors (the “Board”). The Board believes that these changes will position the Company for success in the next phase of its restructuring by adding substantial restructuring experience to the Board. Mr. Jason Bednar, Canacol’s Chief Financial Officer, and Mr. Ravi Sharma, Canacol’s Chief Operating Officer, will assume roles as Interim Co-Chief Executive Officers of the Company effective immediately. Mr. Bednar will continue in his role as Chief Financial Officer and Mr. Sharma will continue in his role as Chief Operating Officer while also assuming the responsibilities as Interim Co-Chief Executive Officers. In this role, they will jointly oversee the Company’s...

LONDON, Feb. 22, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE: NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that it is postponing its Investor Day, originally scheduled for February 24, 2026, due to a state of emergency declared for the New York metropolitan area ahead of a major winter storm, expected to bring blizzard conditions. nVent is currently evaluating scheduling options. A formal invitation will be issued once the new date and location are finalized. This postponement is strictly due to weather-related logistics and is not related to any change in the company’s operations, financial performance or outlook. About nVentnVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems...

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRI axSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease modification in axSpA for SLK As a biomarker-controlled trial, S-OLARIS data showed SLK reduced the levels of key inflammatory mediators in axSpA, in peripheral...